Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer
Open Access
- 31 October 1995
- journal article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 1 (5), 195-198
- https://doi.org/10.1016/1078-1439(95)00061-5
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- 1,25-dihydroxy-16-ene-23-yne-vitamin d3 and prostate cancer cell proliferation in vivoUrology, 1995
- IGF‐Binding proteins in human prostate tumor cells: Expression and regulation by 1,25‐dihydroxyvitamin D3The Prostate, 1995
- Cancer statistics, 1995CA: A Cancer Journal for Clinicians, 1995
- Management of Cancer of the ProstateNew England Journal of Medicine, 1994
- Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.Endocrinology, 1993
- Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I TrialJNCI Journal of the National Cancer Institute, 1993
- Effects of synthetic vitamin d analogues on breast cancer cell proliferation in vivo and in vitroBiochemical Pharmacology, 1992
- 1,25-Dihydroxyvitamin D3 receptors and human colon adenocarcinomaBritish Journal of Surgery, 1991
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, FranceInternational Journal of Cancer, 1977